AI assistant
Merck & Co., Inc. — Director's Dealing 2014
May 14, 2014
284_dirs_2014-05-14_edfdad01-8982-4409-ab68-bf321906f80f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Merck & Co. Inc. (MRK)
CIK: 0000310158
Period of Report: 2014-05-14
Reporting Person: Schechter Adam H (EVP & Pres-Global Human Health)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-05-14 | Common Stock | S | 10527.0000 | $55.9118 | Disposed | 0.0000 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 92794.9747 | Indirect |
Footnotes
F1: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.7800 to $56.1400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: Holdings include shares acquired in dividend reinvestment transactions.